Singh A, Singhal K, Choudhary S, Bisati S, Arora M.
Indian J Dermatol. 2014 May;59(3):316. doi: 10.4103/0019-5154.131459.
PMID:24891683
Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome.
Baghdassarian H, Blackstone SA, Clay OS, Philips R, Matthiasardottir B, Nehrebecky M, Hua VK, McVicar R, Liu Y, Tucker SM, Randazzo D, Deuitch N, Rosenzweig S, Mark A, Sasik R, Fisch KM, Pimpale Chavan P, Eren E, Watts NR, Ma CA, Gadina M, Schwartz DM, Sanyal A, Werner G, Murdock DR, Horita N, Chowdhury S, Dimmock D, Jepsen K, Remmers EF, Goldbach-Mansky R, Gahl WA, O'Shea JJ, Milner JD, Lewis NE, Chang J, Kastner DL, Torok K, Oda H, Putnam CD, Broderick L.
N Engl J Med. 2023 Jun 15;388(24):2241-2252. doi: 10.1056/NEJMoa2202318. Epub 2023 May 31.
PMID:37256972
Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma.
Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, Koch A, Köstler E, Schönlebe J, Haroske G, Doede T, Pramatarov K.
Int J Low Extrem Wounds. 2007 Dec;6(4):291-8. doi: 10.1177/1534734607308731.
PMID:18048875
Disabling pansclerotic morphea of childhood with extracutaneous manifestations.
Kura MM, Jindal SR.
Indian J Dermatol. 2013 Mar;58(2):159. doi: 10.4103/0019-5154.108079.
PMID:23716826
Deep morphea.
Bielsa I, Ariza A.
Semin Cutan Med Surg. 2007 Jun;26(2):90-5. doi: 10.1016/j.sder.2007.02.005.
PMID:17544960
Disabling pansclerotic morphea: clinical presentation in two adults.
Maragh SH, Davis MD, Bruce AJ, Nelson AM.
J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S115-9. doi: 10.1016/j.jaad.2004.10.881.
PMID:16021158
Disabling pansclerotic morphoea: a century of discovery.
Hua VK, Chang J, Laxer RM, Broderick L.
Br J Dermatol. 2025 Mar 18;192(4):585-596. doi: 10.1093/bjd/ljae443.
PMID:39520387
Disabling pansclerotic morphea of childhood--unusual case and management challenges.